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ABSTRACT 
Objective: The main objective of current research work is to develop and validate a rapid, sensitive and selective liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for the trace analysis of four potential genotoxic impurities in Atazanavir Sulfate drug substance. 
Methods: LC-MS/MS analysis of four potential genotoxic impurities was done on Acquity UPLC CSH C18 (100 mm × 2.1 mm, 1.7 μm) column. In this 
method, mobile phase A (10 mM ammonium acetate) mobile phase B (methanol: acetonitrile (90:10, v/v) with gradient run with the flow rate of 0.2 
ml/min. The method was developed with the short run time of 13 min. Triple quadrupole mass detector coupled with positive electrospray 
ionization was used for the quantification of genotoxic impurities in multiple reaction monitoring (MRM) mode. 
Results: The method was linear in the range of 0.3 ppm to 4.5 ppm for BOC Hydrazine Acid impurity, BOC Epoxide and Keto impurity with a 
correlation coefficient not less than 0.9994. The accuracy of the method was in the range of 99.26% to 105.71% for all four potential genotoxic 
impurities (PGIs). No impurities were identified in the Atazanavir Sulfate active pharmaceutical ingredient sample.  
Conclusion: The proposed method is specific, linear, precise, accurate, robust and stable for the quantification of the four genotoxic impurities at 
very low levels. 
Keywords: Atazanavir Sulfate, Genotoxic Impurities, LC-MS/MS, Multiple Reaction monitoring (MRM), Method Development and Validation 
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INTRODUCTION 
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of 
the protease inhibitor (PI) class. Like other antiretroviral, it is used to 
treat infection of the human immunodeficiency virus (HIV). Atazanavir is 
distinguished from other PIs. It can be given once daily (rather than 
requiring multiple doses per day) and has lesser effects on the patient's 
lipid profile (the amounts of cholesterol and other fatty substances in the 
blood). Like other protease inhibitors, it is used only in combination with 
other HIV medications. The U. S. Food and Drug Administration (FDA) 
approved Atazanavir on June 20, 2003. Atazanavir Sulfate is a sulfate salt 
form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent 
on the (hydroxethyl)hydrazine moiety with activity against both wild 
type and mutant forms of HIV protease [1-4]. 
Atazanavir sulfate is chemically designated as (3S,8S,9S,12S)-3,12-
bis(1,1-dimethyl ethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-
[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetra 
decanedioic acid dimethyl ester, sulfate (1:1). Its molecular formula 
is C38H52N6O7. H2SO4, which corresponds molecular weight 802.9. 
According to the literature, the tert-Butyl 2-[4-(pyridine-2-
yl)benzyl]hydrazinecarboxylate (BOC Hydrazine) was identified as a 
potential genotoxic impurity due to the presence of hydrazine, and 
this one is a well-known alerting function for genotoxic activity. 
Tert-butyl{(1S)-1-[(2R)-oxiran-2-yl]-2-phenylethyl}carbamate (BOC 
Epoxide) is identified as potential genotoxic impurity by the 
presence of epoxide. Tertiary butylester[(1S,2S)-3-chloro-2-
hydroxy-1-(phenylmethyl) propyl]carbamicacid (Acid impurity) and 
3(S)-3-(tert-butoxycarbonyl)amino-1-chloro-4-phenyl-2-butanone 
(Keto impurity) has alert functional group of carbamates. The 
genotoxic alert for these impurities was identified through DEREK 
nexus software [5]. LHASA predictions derived out of DEREK nexus 
software report clearly indicate that those impurities are a very 
plausible entity that shows carcinogenicity, chromosome damage in 
vitro, and mutagenicity in mammals.  
The international regulatory bodies from various regions have been 
emphasized the determination of impurities in the drug substances 
and drug products because of their toxicological concern [6, 7]. 
Genotoxic impurities are those that have the potential to cause 
cancer. These impurities (GTIs) carry to a drug substance in the 
manufacturing process as starting materials, reagents, 
intermediates, by-products, degradants, etc. If an impurity contains 
a structural alert for mutagenicity, it can be considered as a 
genotoxic impurity [8, 9]. The European Medicines Agency released 
guidelines on the control of GTI and ICH also released guidelines on 
Genotoxic impurities [ICH M7] [10, 11]. These guidelines proposed a 
threshold of toxicological concern value (1.5 µg/d).  
According to the guidelines of regulatory agencies, the amount of these 
four genotoxic impurities in the Atazanavir sulfate should be limited to 
3.75 ppm by assuming of maximum daily dosage of Atazanavir sulfate as 
400 mg/day dose [12-14]. Accurate determination of very low level i.e., 
ppm levels, the hyphenated techniques are very inadequate, and 
consequently, there is a great need to develop a sensitive analytical 
method for the analysis of such genotoxic impurities in pharmaceutical 
industries. Thus, various kinds of separation techniques, methodologies 
have been explored as useful approaches out of Hsieh and Korfmacher 
[15], and Lee and Kerns [16] had discussed LC-MS/MS technique and 
application. 
Several research papers have been reported in the literature for the 
determination of Atazanavir sulfate stability indicative methods by 
HPLC [17-23]. No methodology was available for Acid impurity and 
Keto impurity at individuals and also for the combination of four 
genotoxic impurities as well. The structures of Atazanavir sulphate 
and four genotoxic impurities are presented in fig. 1. 
MATERIALS AND METHODS  
Chemicals  
Acetonitrile and methanol with HPLC grade were obtained from 
Merck (Mumbai, India). Ammonium acetate of analytical grade was 
supplied by Sigma Aldrich Limited (Mumbai, India). Atazanavir 
Sulfate API and reference substances of genotoxic impurities were 
obtained from HTS Biopharma, Hyderabad. 
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Compound Name: BOC Hydrazine
Molecular Formula: C17H21N3O2
Molecular weight: 299.37






















Fig. 1: Chemical structures of atazanavir sulfate and its genotoxic impurities 
 
Instrumentation 
The MS of LC-MS/MS system used was an Mass Quattro micro API 
model (Waters). The ultra-performance liquid chromatography 
(UPLC) with photodiode array detector (Waters, Milford, US). As 
part of experimentation, additional equipment such as sonicator 
(22L500/CC/DTX) and Semi microbalance (MX3, Mettler Toledo, 
Switzerland) was also used for method development and validation. 
Data acquisition and processing were conducted using the Masslynx 
4.1 software on a Dell computer. 
Chromatographic and mass conditions 
Results were obtained in gradient mode using a mobile phase 
consisting of a degassed mixture of 10 mM Ammonium acetate in 
water as mobile phase A, Methanol, and acetonitrile in the ratio of 
90:10. Other conditions include column: Acquity UPLC CSH C18 (100 
mm x 2.1 mm, 1.7 µm) (make: waters), Column temperature: 45 °C, 
flow rate: 0.2 ml/min, injection volume: 7.0 µl. 
The all four impurities ionization in a positive mode in the presence 
of electrospray ionization with the scan range of 50 to 1000 m/z. 
Remaining parameters Include Capillary voltage (kV): 2.0, Cone 
voltage (V): 30, Source temperature: 120 °C, Desolvation 
temperature: 500 °C, Desolvation gas (L/h): 1000 and scan type: 
Multiple reaction monitoring (MRM). 
Method development and optimization 
The present liquid chromatography-tandem mass spectrometry 
method was initiated by testing different stationary phases to 
achieve good separation of the four genotoxic impurities with the 
Atazanavir drug substance [29]. It is important to achieve proper 
separation among the four potential genotoxic impurities (PGI's) 
and Atazanavir sulfate because of the analogous chemical structure 
of four genotoxic impurities with Atazanavir sulfate [30, 31]. 
Initially, the method started with a mobile phase consisting of 
mobile phase A and mobile phase B in equal proportions in isocratic 
mode by using C18column, but keto impurity was not eluted till 15 
min. In order to obtain well separation within a short analysis time, 
various analytical columns like Kinetex C18 (150 mm × 2.1 mm, 1.7 
μm), Hypersil gold (100 mm × 2.5 mm, 1.9 μm), Acquity UPLC CSH 
C18 (100 mm × 2.1 mm, 1.7 μm) with gradient programme were 
evaluated under the similar conditions. When the Kinetex C18 
column was used, the Keto impurity peak overlapped with 
Atazanavir peak. The resolution between Atazanavir and impurities 
was poor when the Hypersil gold column was used. An Acquity UPLC 
CSH C18 (100 mm × 2.1 mm, 1.7 μm), the resolution of four 
genotoxic impurities, and Atazanavir were found good along with 
good mass sensitivity. Finally, the analysis was carried out on 
Acquity UPLC CSH C18 as retention and separation of four genotoxic 
impurities from Atazanavir drug substance were good. Different 
compositions of mobile phases using 0.1% formic acid and 10 mM 
ammonium acetate with acetonitrile were tested. Finally, good 
separation and response were observed when mobile phase 
consisting of mobile phase A (10 mM ammonium acetate) mobile 
phase B (methanol: acetonitrile (90:10, v/v)) with gradient run. The 
column was thermostated at 45 °C to avoid any shift in retention 
time and better peak shape. 
Optimization of MS/MS conditions 
Here LC/MS/MS analysis started with electrospray ionization (ESI) 
source in positive mode with multiple reaction monitoring (MRM). 
Generally, MRM mode shows high sensitivity than single ion 
monitoring (SIM). Multiple reaction monitoring has one more 
advantage than SIM mode that both parent ion and fragment ion 
monitored in a single analysis, but in the case of SIM mode, only a 
single ion i.e., either parent or daughter ion only, can monitor.  
BOC Hydrazine was injected and found its m/z as 300 (protonated), 
then it is fragmented with 30 volts of collision energy found more 
predominant stable fragment ion with its m/z of 168.1 (daughter 
ion). Finally, BOC hydrazine was monitored with its mass transition 
between m/z of 300 to 168.1. BOC Epoxide was injected and found 
its protonated ion with sodium adduct (m/z as 286.2) with lower 
sensitivity and fragmented ion of m/z 164.1 with high sensitivity. So 
fragmented ion of m/z of 164.1 further fragmented with 30 volts of 
collision energy to get predominant stable fragment ion m/z of 
129.1 (daughter ion), so BOC Epoxide was monitored with its mass 
transition from m/z of 164.1 to 129.1. Acid impurity was injected 
and found its m/z as 322 for a protonated ion with sodium adduct, 
further it is fragmented with 30 volts of collision energy and found 
more predominant stable fragment ion with m/z of 200.16 as a 
daughter ion, so Acid impurity was monitored with its mass 
transition from 322 to 200.2. Keto impurity was injected and found 
its m/z as 320 for a protonated ion with sodium adduct, further it is 
fragmented with 30 volts of collision energy and found more 
predominant stable energy and found more predominant stable 
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fragment ion with m/z of 198.2 as a daughter ion, so Keto impurity 
was monitored with its mass transition from 322 to 200.2.  
Preparation of solutions 
Diluent: Used a degassed mixture of methanol and water in the ratio 
of 85:15 v/v. 
Preparation of standard stock solution 
Accurately weighed and transferred 25 mg of each genotoxic 
reference standard taken separately into four different individual 
100 ml volumetric flasks and diluted up to the mark to get 0.25 
mg/ml of stock solution. Further, each 0.5 ml of the above solutions 
taken into a 100 ml volumetric flask and diluted with diluent. 
Further diluted 5 ml above solution into a 50 ml volumetric flask 
and diluted with diluent. 
Preparation of standard solution 
1.5 ml of the above standard stock solution is taken into 50 ml 
volumetric flask and diluted up to the mark with diluent to get the 
standard solution of 0.00000375 mg/ml, which is equivalent to 3.75 
ppm with respect to sample concentration of 1 mg/ml. 
Spiked (specification level) sample preparation 
Accurately weighed and transferred 50 mg of Atazanavir sulfate into 
a 50 ml volumetric flask to get the sample concentration of 1 mg/ml, 
to this 1.5 ml standard stock solution was added and diluted to 
volume with diluent. 
Sample preparation 
Weighed about 50 mg of Atazanavir sulfate into 50 ml volumetric 
flask dissolved and diluted to volume with diluent. 
RESULTS AND DISCUSSION 
Research papers available for individual genotoxic impurities of BOC 
Hydrazine [24]. The reported method containing isocratic elution 
and used the single ion monitoring (SIM) method by HPLC-MS. For 
this method, the quantification limit is 1.1 ppm and run time 15 min. 
According to literature [25], the authors reported that, the BOC 
epoxide impurity was found quantification limit was 0.5 ppm by 
isocratic mode and run time was 15 min through HPLC. In this 
published paper, the authors are not used the multiple reaction 
monitoring (MRM) technique for the detection of stable fragments. 
In the present study, we developed a simple LC-MS/MS method that 
can quantify (below 0.3 ppm) the BOC Hydrazine, BOC Epoxide, Acid 
impurity, and Keto impurity at a lower level in Atazanavir sulphate. 
Analysis was carried out with gradient mode and multiple reaction 
monitoring (MRM) method for the detection of stable fragments to 
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Fig. 2: Fragmentation of genotoxic impurities 
 
As per the literature review, this is the first LC-MS/MS method 
developed for the determination for the detection and quantification 
of BOC Hydrazine, BOC Epoxide, Acid impurity, and Keto impurity 
simultaneously. The method is validated as per ICH guidelines in 
terms of limit of detection (LOD), the limit of quantification (LOQ), 
linearity, precision, accuracy, specificity, and robustness [26-28].  
Method validation 
Validation provides assurance about the method or process 
regarding the quality standard of the analytical method is assured by 
performing the validation of the developed method withQ2 
specifications of ICH guidelines. 
System suitability 
The system suitability test was performed before each run to 
assure that the developed LC-MS/MS method exhibits 
satisfactory performance. It is evaluated by injecting the six 
injections of standard solution and calculating the % RSD of 
areas of all impurities. The data generated in this test is 
presented in table 1. 
 
Table 1: System suitability results of four genotoxic impurities 
S. No. Components Average area (n=6)* SD % RSD 
1 BOC Hydrazine 306484 4866.2 1.59 
2 BOC Epoxide 114023 1678.8 1.47 
3 Acid impurity 120626 1197.3 0.99 
4 Keto impurity 99387 1878.7 1.89 
*Number of injections done (n):6. 
 
Specificity 
Specificity of the present LC-MS/MS method was checked by 
injecting the blank, four individual genotoxic impurities and 
Atazanavir sulfate sample and sample spiked with four genotoxic 
impurities. There was no interference of the main drug with 
impurities and the developed method was adequately resolved four 
genotoxic impurities with each other and with the main drug. 
Results presented in table 2 and representative spectra presented in 
fig. 3. 
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Table 2: Summary of specificity 
Name of the component RT (min)* m/z molecular ion (Protonated)  m/z fragment ion (Protonated) 
BOC Hydrazine  4.5 300.1 168.1 
Acid impurity  6.2 322[M+Na] 200.1 
BOC Epoxide  6.9 286[M+Na] 164.1 
Keto impurity  8.6 320[M+Na] 198.1 




Fig. 3: Chromatograms of the specificity of the impurities with atazanavir 
 
Linearity and sensitivity 
The linearity of the method in multiple reaction monitoring mode 
was satisfactorily demonstrated by injecting the four genotoxic 
impurities individually at different levels of concentrations ranges 
from LOQ (0.3 ppm) and 120% (4.5 ppm) of the specification 
concentration (3 ppm). The calibration curves were plotted between 
the peak areas and concentration of four genotoxic impurities at 
include 0.3, 1.5, 2.25, 3, and 4.5 ppm for LOQ, 40, 60, 80, 100, 120% 
specification levels, respectively. 
The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated from S/N (signal to noise) ratios. In this process, the 
concentrations were reduced sequentially in such a way to yield an 
S/N ratio. Results are represented in table 3 and linearity curves in 
fig. 4. 
 
Table 3: Linearity and sensitivity results of four genotoxic impurities 
Parameter BOC hydrazine Acid impurity BOC epoxide Keto impurity 
Range (ppm) 0.298-4.459 0.299-4.468 0.298-4.458 0.288-4.475 
Correlation* 0.9998 0.9995 0.9995 0.9996 
Slope** 97662.466 35021.962 31352.230 30996.371 
Intercept -5486.091 -1861.835 891.973 1556.560 
LOD (ppm) 0.10 0.10 0.11 0.10 
S/N 3.4 2.5 2.8 3.3 
LOQ (ppm) 0.298 0.299 0.298 0.288 
S/N 10.4 9.9 9.8 10.5 
LOQ Precision (n=6)#     
Mean area 27120 11073 12141 10227 
SD 656.6193 410.5604 244.8031 338.7034 
%RSD 2.42 3.71 2.02 3.31 
*Correlation coefficient, **Y is the peak area, and X is the concentration has taken, #Number of experiments done (n):6 
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Fig. 4: Linearity curves of genotoxic impurities 
 
Precision 
The precision of the method was determined by analyzing six 
individual samples of Atazanavir spiked with each impurity at 100% 
of the specification limit on the same day, and Intermediate 
precision was evaluated by analyzing six individual samples of 
Atazanavir spiked with each impurity at 100% of the specification 
limit on the other day. The obtained results were given in table 4 
and the representative chromatogram in fig. 5. 
Accuracy 
To ensure the accuracy of the method, a Percentage recovery 
technique was adopted where spiking the four genotoxic impurities 
at LOQ level, 50%, 100%, and 120% of the specification 
concentrations i.e., 0.3, 1.875, 3.75, and 4.5 ppm with respect to the 
sample concentration of 1 mg/ml of Atazanavir. Each determination 
was carried out in triplicate. The percentage recovery values 
obtained at LOQ to 120% levels were in the range of 99.3-105.7 
(table 5, 6), which significantly gives out the accuracy of the 
concerned method as of ICH limits. 
Robustness 
The robustness of the present LC-MS/MS method was checked by 
deliberate changes in flow rate and column temperature in liquid 
chromatography and source temperature in the mass source. The 
effect of the flow rate of the mobile phase on the separation of three 
genotoxic impurities was studied by changing the actual flow (0.2 
ml/min) rate by 10%, i.e., at 0.18 and 0.22 ml/min. The effect of 
column temperature on the analysis was studied by changing the 
temperature by two units, i.e., at 42 °C and 47 °C (temperature 
altered by two units). The robustness of the proposed method was 
also evaluated by changing the temperature in the mass source 
with±20 °C. Results obtained from robustness were mention in 
tables 7 to 10. 
  
Table 4: Method precision and intermediate precision results of four impurities 
Parameter BOC hydrazine Acid impurity BOC epoxide Keto impurity 
Method precision (n=6)* 
Mean (ppm) 3.84 3.58 3.32 3.59 
SD 0.0350 0.0426 0.0308 0.0383 
%RSD 0.9 1.2 0.9 1.1 
Intermediate precision (n=6)* 
Mean (ppm) 3.62 3.71 3.44 3.72 
SD 0.0647 0.0539 0.0605 0.0736 
%RSD 1.8 1.5 1.8 2.0 
Cumulativeprecision (n=12)# 
Mean (ppm) 3.73 3.65 3.38 3.65 
SD 0.1251 0.0829 0.0755 0.0893 
%OverallRSD 3.4 2.3 2.2 2.4 
*Number of experiments done (n):6, #Number of experiments done (n):12 (cumulative results of both method precision and intermediate precision. 
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Fig. 5: Representative chromatograms of the precision 
 
Table 5: Accuracy results of four impurities at LOQ level 
Component Amount added (ppm) Amount found (ppm) % Recovery Mean recovery SD* %RSD 
 n=3# 
BOC Hydrazine 0.2963 0.3016 101.79 101.0 0.674 0.7 
0.2986 0.3004 100.60 
0.2956 0.2975 100.64 
Acid impurity 0.2971 0.3010 101.31 101.5 0.445 0.4 
0.2946 0.3008 102.10 
0.2956 0.3092 104.60 
BOC Epoxide 0.2897 0.2956 102.04 102.8 1.115 1.1 
0.2946 0.3012 102.24 
0.2856 0.2972 104.06 
Keto impurity 0.2997 0.3010 100.43 100.8 0.329 0.3 
0.2986 0.3012 100.87 
0.2965 0.2997 101.08 
*Standard deviation, #Number of experiments done (n):3 
 
Table 6: Accuracy results of four genotoxic impurities 
% of spec Amount added (ppm) Amount found (ppm) % Recovery Mean recovery SD %RSD 
 n=3* n=9* 
BOC Hydrazine   103.4 1.108 1.1 
50% 1.8491 1.8803 101.7 
100% 3.6376 3.7672 103.6 
120% 4.3533 4.5612 104.8 
Acid impurity 101.8 0.680 0.7 
50% 1.8599 1.8884 101.5 
100% 3.6603 3.7562 102.6 
120% 4.3822 4.4379 101.3 
BOC Epoxide 101.0 0.909 0.9 
50% 1.7774 1.7760 99.9 
100% 3.5795 3.6892 103.1 
120% 4.1897 4.1925 100.1 
Keto impurity 102.1 0.680 0.7 
50% 1.8498 1.8705 101.1 
100% 3.6603 3.7562 102.6 
120% 4.3499 4.4617 102.6 
*Number of experiments done at each level (n):3, cumulative recovery for all three levels (n):9 
 
Table 7: Robustness impact on BOC hydrazine from system suitability solution 
Parameter Variation Retention time (min) %RSD 
Actual -- 4.5 1.59 
Flow rate (±10%) 0.18 ml/min 4.7 1.03 
0.22 ml/min 4.3 0.69 
ColumnOven temp (±2 units) 42 °C 4.6 1.24 
47 °C 4.3 0.97 
Desolvation temperature and gas 980 4.5 1.24 
1020 4.5 1.02 
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Table 8: Robustness impact on acid impurity from system suitability solution 
Parameter Variation Retention time (min) %RSD 
Actual -- 6.2 0.99 
Flow rate (±10%) 0.18 ml/min 6.8 1.47 
0.22 ml/min 6.0 2.68 
ColumnOven temp (±2 units) 42 °C 6.7 1.14 
47 °C 6.0 0.89 
Desolvation temperature and gas 980 6.2 3.41 
1020 6.2 1.15 
 
Table 9: Robustness impact on BOC epoxide from system suitability solution 
Parameter Variation Retention time (min) %RSD 
Actual -- 6.9 1.47 
Flow rate (±10%) 0.18 ml/min 7.1 1.81 
0.22 ml/min 6.7 0.60 
ColumnOven temp (±2 units) 42 °C 6.6 0.92 
47 °C 6.9 1.49 
Desolvation temperature and gas 980 6.9 1.15 
1020 6.9 1.24 
 
Table 10: Robustness impact on Keto impurity from system suitability solution 
Parameter Variation Retention time (min) %RSD 
Actual -- 8.7 1.89 
Flow rate (±10%) 0.18 ml/min 8.9 3.58 
0.22 ml/min 8.5 1.43 
ColumnOven temp (±2 units) 42 °C 8.9 1.20 
47 °C 8.6 1.48 
Desolvation temperature and gas 980 8.7 0.94 
1020 8.7 1.54 
 
Solution stability 
To prove the stability of these four impurities, standard solution and 
the spiked solution were kept at refrigerator (2-8 °C) conditions and 
room temperature (25 °C) for 24 h. It was found that the amount 
recovered from both fresh and stored solutions was highly similar. 
CONCLUSION 
In the earlier period, a number of RP-HPLC were developed for 
estimation of Atazanavir sulfate and its impurities in pure and 
dosage form. Only two LC-MS/MS methods were reported for the 
determination of GTI's such as BOC Hydrazine and epoxide. But 
single LC-MS/MS method for estimation of all the four GTI's was not 
yet established. The present LC-MS/MS method has the ability to 
separate and quantify all the four GTI's at trace level. The RT gained 
for all the four GTI's was less with the simple solvent system in 
gradient mode. Therefore the method has good adaptability in the 
pharmaceutical industry for analysis of Atazanavir sulfate.  
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